Best Truse Experts Latest Laboratory Technlogy
It is a long established fact that a reader will be distracted by the readable content of a page when at layout The point of using Ipsum.
Clinical Chemestry
Research & Development
- There are many variations of passages of Lorem Ipsum available
- Contrary to popular belief, Lorem Ipsum is not simply random
- Lorem Ipsum is simply dummy text of the printing
Our Feature Projects
We’ll Ensure You Always Get The Best Result
Meet Our laboratory expert
Alex Jhon Martin
Web DesignerAlexa Jhon
Web DesignerNaidan Smith
Web DesignerDanial Frankie
Web DesignerDanial Frankie
Web Designersee Our Latest Blog
- admin
- news
SmartHealth Dx Featured in Cover Story of Med Tech Outlook Magazine’s Pathology Special Edition
IRVINE, Calif., June 13, 2023 /PRNewswire/ — Smart Health Diagnostics Company (“SHDx” or “the Company”), a developer of precision diagnostic tests that address unmet clinical needs in pathology and vascular inflammation for advancing today’s standards of care, announced that CEO and Chairman Mitch Levine is featured in the June 8, 2023 edition of Med Tech […]
- admin
- news
Specialty Diagnostics Technology and Solutions Provider Unveils New Brand Identity as SmartHealth Diagnostics
SmartHealth name unifies multi-function operating platform with smart science diagnostics product suite under common brand
- admin
- news
SmartHealth Diagnostics Appoints Accomplished Corporate and Finance Leader Mitch Levine as President, Chief Financial Officer, and Director
Highly regarded diagnostics industry executive and capital markets expert to guide planned growth and value creation for evolutionary data-to-diagnostics platform company
- admin
- news
Diagnostic Tests to Improve Patient Care
Company announces its business strategy including test development, commercialization, intellectual property, and reimbursement initiatives
- admin
- news
Predictive Health Diagnostics Company Welcomes Susie Lu as President of Laboratory Services for All Company Businesses
Susie Lu as President of Laboratory Services for all Predictive Health Diagnostics Company businesses.
- admin
- news
Predictive Health Diagnostics Company Appoints 30-Year Diagnostic Imaging Executive Larry Dentice as Chief Commercial Officer and Director
Larry Dentice as Chief Commercial Officer. Mr. Dentice has also stepped into a board role following the departure of longtime board member Munira Mubarak.
- admin
- news
Predictive Health Diagnostics Company’s Morningstar Laboratories Receives Clinical Laboratory Permit from Pennsylvania Department of Health
Morningstar to bring much needed laboratory service resources, including COVID-19 antibody testing, to urban and rural communities statewide
- admin
- news
Predictive Health Diagnostics Company’s PULS Cardiac Test Plays Key Role in Detecting Vascular Inflammation Common After Receiving COVID-19 Vaccines
PULS Test vascular inflammation biomarkers and scores reveal risk of developing acute coronary syndrome (ACS) which can be increased in mRNA COVID-19 vaccinated patients
- admin
- news
Predictive Health Diagnostics Company Expands Smart Science Diagnostics Platform with Acquisition of MUSE Microscopy Inc.
AI-derived imaging platform expands Company’s test development expertise to create next generation diagnostics for pathology
- admin
- news
Predictive Health Diagnostics Company Announces Rollout of Proprietary LIS Cloud-Based Laboratory Information System Software
LIS system enables scalable functionality and big data analysis capabilities
- admin
- news
Predictive Health Diagnostics Company’s Morningstar Laboratories Reports Expanding In-Network Provider Participation, Achieves Accreditation from College of American Pathologists (CAP)
Expanding in-network status reflects strong demand and utilization of the PULS Cardiac Testâ„¢ and DIABETESpredictâ„¢ in healthcare settings nationwide
- admin
- news
Predictive Health Diagnostics Company Announces Partnership with Madison Core Laboratories for PULS Cardiac Testâ„¢ Distribution to 30+ Healthcare Facilities
Distribution targeted to high at-risk co-morbid patient populations